Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Sailer

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Therapeutic Innovation & Regulatory Science|October 7, 2024
Pharmacometrics-Enhanced Bayesian Borrowing for Pediatric Extrapolation - A Case Study of the DINAMO TrialMartin Oliver Sailer, Dietmar Neubacher, Curtis Johnston, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand FrameworkEvgeny Degtyarev, Kaspar Rufibach, Yue Shentu, et al.
Pharmaceutical Statistics|November 6, 2020
Estimand framework: Are we asking the right questions? A case study in the solid tumor settingMichelle Casey, Evgeny Degtyarev, María José Lechuga, et al.
The Lancet. Oncology|November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trialAndreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Therapeutic Innovation & Regulatory Science|October 7, 2024
Pharmacometrics-Enhanced Bayesian Borrowing for Pediatric Extrapolation - A Case Study of the DINAMO TrialMartin Oliver Sailer, Dietmar Neubacher, Curtis Johnston, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand FrameworkEvgeny Degtyarev, Kaspar Rufibach, Yue Shentu, et al.
Pharmaceutical Statistics|November 6, 2020
Estimand framework: Are we asking the right questions? A case study in the solid tumor settingMichelle Casey, Evgeny Degtyarev, María José Lechuga, et al.
The Lancet. Oncology|November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trialAndreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
Pageof 2